

Present; Nina, Barbara, alejandro, Andreas, Toni, Bru, Jonna, Marta

Agenda:

1. To-do-list
2. Should we open up the IMPACT TC every second month for all ECNP Network members during the second 30 minutes of the TC? Actionpoint 3
3. IMPACT meeting 2016 or 2017? Actionpoint 2
4. Update projects
 - a. Progress adult ADHD GWAS MA (Marta)
5. News projects plans 2016 **Plans 2016**
6. Update on additional exciting new results coming from individual IMPACT labs to be shared prior to publication (all)
7. Updating website
8. Others

To-do-list

		who	Deadline
1	Marta has sent results comparisons of RNA isolation. Agendapoint 4a	All	Next meeting
2	Janneke asked also if other employees working on Impact should also receive a login. Janneke will send a reminder. Done	Angelien/ Janneke	Next meeting
3	IMPACT meeting 2016 yes or no or in combination with other meetings . Angelien send an email. No IMPACT meeting in 2016 but in the first part of 2017	Angelien	Next meeting
4	Representation Eunthydis Barbara send an email. Done	Barbara	Next meeting

1. To-do-list
2. Should we open up the IMPACT TC every second month for all ECNP Network members during the second 30 minutes of the TC? Every second month 30 minutes ECNP and 30 minutes IMPACT
3. IMPACT meeting 2016 or 2017? Actionpoint 2
4. Update projects
 - A. Progress adult ADHD GWAS MA (Marta)
On March 9th the IMPACT meta-analysis plan is distributed. The proposed deadline was 1st June but to date we just received results from the Netherlands. The deadline will be extended until September 1st. Marta will send the analysis plan to Nina. Nina

would like to compare their analysis plan with the analysis plan that is advice at the summerschool in London. Marta will send a reminder and we stick to the first analysisplan.

5. News projects plans 2016 **Plans 2016**

A. Netherlands: Alejandro/Barbara ??????

- CDH13 – rare and common variants and their role in ADHD and its comorbidities (those relevant to CoCA): CDH13 analysis on hold, waiting for the GWAS results
- Meta-analysis of the adult ADHD GWAS-MA (from Spain) and SAGA (adult ADHD traits in the population) (Marieke Klein): we are waiting for the GWAS results from Spain. Dutch samples as controls for the replication
- Microbiom project with Brazil and Spain: In the setting up phase
- Epigenetics: Working with John Miller, Candidate pathway analysis on adult ADHD samples. There are epigenetic data from 100 patients. Material for epigenetic analysis from 300 cases and 300 controls. Material is analyzed on the Illumina platform, Barbara will send an email to ask for material for epigenetic analysis.

B. UK: Jonna

- CoCA clinical trial. Data collection will start in Autumn
- MiND: polygenic prediction – potentially one could use Marta's results from the adult ADHD GWAS-MA to see predictive value for persistence . Waiting for the ADHD GWAS results
- Swedish registry data with Henrik—Interesting results
- Prison cohort : no news Philip is not on the call.

C. USA: Steve no news

- ADHD GWAS-MA not yet done
- Data analysis using the PGC; importantly, the PGC3 NIH grant got very good scores, and it will employ several data analysts, so that the PGC data becomes available to a greater community
- Method to measure malingering, which seems to occur in adults feigning ADHD

D. Sweden: Henrik no news

- Work related to CoCA - mainly WP1
- Initiate a pilot-study for large-scale population-based data collection of adult ADHD cases
- Birth month, ADHD and adult outcomes. Register study with Jonna Kuntsi.
- Continue to encourage IMPACT members to use Swedish registers in studies of ADHD.
- (ECNP symposium discussant for TNM about registry-studies of ADHD in Vienna.

E. Barcelona: Marta

- Epigenetics analysis in MiND
Niall will join our group by the beginning of next year. He is now in Wurzburg working on mouse models and stressful live events. Barbara ask if it also possible to get a blood sample from the participant after treatment
- Microbiom analysis together with Alejandro
We got funding and are now recruiting samples. In total we recruited samples from 30 ADHD cases naive for pharmacological treatment and no comorbidity and 4 controls in which ADHD diagnosis was excluded.
- Cannabis use – ADHD GWAS-MA
We got dbGAP and NIMH permission to get access to ADHD data and received summary statistics for Cannabis Use from the Cannabis Consortium. We'll start with the analysis one we get access to lisa from the PGC.
- Expression analysis
As mentioned, we found batch effects on our expression assays and distributed our optimized protocol for RNA extraction in case other IMPACT groups are interested on expression assays.

